# Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

> **NCT05591755** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 229 (actual)

## Conditions studied

- Seasonal Allergic Conjunctivitis

## Interventions

- **DRUG:** Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
- **DRUG:** Ketotifen fumarate ophthalmic solution 0.035%
- **DRUG:** Brimonidine tartrate ophthalmic solution 0.025%
- **DRUG:** Experimental: Vehicle ophthalmic solution

## Key facts

- **NCT ID:** NCT05591755
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-18
- **Primary completion:** 2023-08-09
- **Final completion:** 2023-08-09
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05591755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05591755, "Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05591755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*